Potential prognostic value of PD-L1 and FOXP3 as predictors of relapse in breast cancer
暂无分享,去创建一个
[1] P. Fasching,et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. , 2019, European journal of cancer.
[2] K. Okoń,et al. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status , 2019, Virchows Archiv.
[3] Jun Jiang,et al. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer , 2019, Medicine.
[4] Yan Wang,et al. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting , 2019, Cancer biology & therapy.
[5] Yang Wu,et al. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma , 2018, Medicine.
[6] X. Ren,et al. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer , 2018, Cancer biology & therapy.
[7] Qiaohong Wang,et al. Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer , 2017, International immunopharmacology.
[8] P. Tan,et al. Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.
[9] M. Disis,et al. Clinical significance of tumor-infiltrating lymphocytes in breast cancer , 2016, Journal of Immunotherapy for Cancer.
[10] J. Madore,et al. Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome , 2016, Histopathology.
[11] Shuai Li,et al. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient , 2016, Journal of Cancer.
[12] F. Bertucci,et al. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers , 2016, Oncoimmunology.
[13] J. Joo,et al. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. , 2016, Clinical breast cancer.
[14] L. Sarian,et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. , 2016, Human pathology.
[15] C. Caldas,et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Yong Song,et al. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. , 2015, Translational lung cancer research.
[17] Jingting Jiang,et al. B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. , 2014, International journal of clinical and experimental pathology.
[18] F. Gao,et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.
[19] Vamsidhar Velcheti,et al. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.
[20] O. Woo,et al. Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer , 2013, American journal of clinical oncology.
[21] K. Shirouzu,et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis , 2013, Molecular and clinical oncology.
[22] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[23] D. Yin,et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.
[24] J. Cheville,et al. Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma , 2011, Clinical Cancer Research.